Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Diagnostic performance of low-dose chest CT scan combined with lung-RADS classification (version 1.1) for lung cancer screening among former and current smokers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CT scan | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low-dose chest CT scan | Diagnostic Test | baseline, 1-year, 3-year and 5-year low-dose CT scan |
|
| Measure | Description | Time Frame |
|---|---|---|
| Positive Predictive Value (PPV) | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity | 5 years | |
| Specificity | 5 years | |
| Early stage lung cancer detection rate (stage I and II) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Cecile Bielmann | Contact | 0033488731070 | cbielman@hopital-saint-joseph.fr |
| Name | Affiliation | Role |
|---|---|---|
| Arnaud Boyer, MD | Hopital Saint Joseph Marseille | Principal Investigator |
| Illies Bouabdallah, MD | Hopital Saint Joseph Marseille | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Saint Joseph | Recruiting | Marseille | France |
Not provided
| ID | Term |
|---|---|
| D012907 | Smoking |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 years |
| 5-year survival rate of patients who have undergone thoracic surgery | 5 years |
| Rate of smoking-related co-morbidities detected on low-dose CT scan | smoking-related co-morbities = pulmonary emphysema, interstitial lung disease, atheromatous disease, hepatic steatosis and ascending aortic aneurysm. | 5 years |
| Rate of additional examinations (including invasive diagnostic tests and surgery with benign results) | 5 years |
| Risk ratio of lung cancer | 5 years |
| Number of false positive results | 5 years |
| Penetration rate | number of subjects included / number of includible subjects | 5 years |
| Smoking cessation rates | 5 years |
| EORTC QLQ-C30 score (version 3) | The EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions. The EORTC QLQ-C30 is composed of 9 multi-item scales: 5 functioning scales (physical, role, cognitive, emotional and social), a global QOL scale, and 3 symptom scales (fatigue, pain and nausea/vomiting). In addition, several single item symptom measures are used. For the five functioning scales and the global quality of life scale, a higher score represents a better level of functioning. For the symptom scales and items, a high score corresponds to a higher level of symptomatology. | 5 years |